Anne Li April 23rd, 2017
It’s been a couple of years since the genome editing tool CRISPR first hit the headlines. And talk of its potential to cure all manner of diseases, create superhumans and bring dinosaurs back from the dead has followed. But among that speculation, one area of medicine has been quick to pick up the technology and is now leading the way in early clinical trials. In this second post in our series taking a closer look at CRISPR, we explore its potential for new developments in cancer immunotherapy.
See original article at: http://scienceblog.cancerresearchuk.org/2017/04/21/crispr-genome-editing-and-immunotherapy-the-early-adopter/